



**21** ST EDITION

---

# *Remington*

## **The Science and Practice of Pharmacy**



**LIPPINCOTT WILLIAMS & WILKINS**

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

Editor: David B. Troy  
Managing Editor: Matthew J. Hauber  
Marketing Manager: Marisa A. O'Brien

Lippincott Williams & Wilkins

351 West Camden Street  
Baltimore, Maryland 21201-2436 USA

530 Walnut Street  
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturer's product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions.

Printed in the United States of America

Entered according to Act of Congress, in the year 1885 by Joseph P Remington, in the Office of the Librarian of Congress, at Washington DC

Copyright 1889, 1894, 1905, 1907, 1917, by Joseph P Remington

Copyright 1926, 1936, by the Joseph P Remington Estate

Copyright 1948, 1951, by the Philadelphia College of Pharmacy and Science

Copyright 1956, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, by the Philadelphia College of Pharmacy and Science

Copyright 2000, 2006, by the University of the Sciences in Philadelphia

All Rights Reserved

Library of Congress Catalog Card Information is available  
ISBN 0-7817-4673-6

*The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.*

*The use of structural formulas from USAN and the USP Dictionary of Drug Names is by permission of The USP Convention. The Convention is not responsible for any inaccuracy contained herein.*

*Notice—This text is not intended to represent, nor shall it be interpreted to be, the equivalent of or a substitute for the official United States Pharmacopeia (USP) and/or the National Formulary (NF). In the event of any difference or discrepancy between the current official USP or NF standards of strength, quality, purity, packaging and labeling for drugs and representations of them herein, the context and effect of the official compendia shall prevail.*

To purchase additional copies of this book call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

# Contents

<b>Part 1 Orientation</b>	
1	Scope of Pharmacy . . . . .3
2	Evolution of Pharmacy . . . . .7
3	Ethics and Professionalism . . . . .20
4	The Practice of Community Pharmacy . . . . .30
5	Pharmacists in Industry . . . . .35
6	Pharmacists in Government . . . . .40
7	Pharmacists and Public Health . . . . .51
8	Information Resources in Pharmacy and the Pharmaceutical Sciences . . . . .64
9	Clinical Drug Literature . . . . .74
10	Research . . . . .87
<b>Part 2 Pharmaceutics</b>	
11	Metrology and Pharmaceutical Calculations . . . . .99
12	Statistics . . . . .127
13	Molecular Structure, Properties, and States of Matter . . . . .162
14	Complex Formation . . . . .186
15	Thermodynamics . . . . .201
16	Solutions and Phase Equilibria . . . . .211
17	Ionic Solutions and Electrolytic Equilibria . . . . .231
18	Tonicity, Osmoticity, Osmolality, and Osmolarity . . . . .250
19	Chemical Kinetics . . . . .266
20	Interfacial Phenomena . . . . .280
21	Colloidal Dispersions . . . . .293
22	Coarse Dispersions . . . . .319
23	Rheology . . . . .338
<b>Part 3 Pharmaceutical Chemistry</b>	
24	Inorganic Pharmaceutical Chemistry . . . . .361
25	Organic Pharmaceutical Chemistry . . . . .386
26	Natural Products . . . . .410
27	Drug Nomenclature—United States Adopted Names . . . . .443
28	Structure-Activity Relationship and Drug Design . . . . .468
29	Fundamentals of Medical Radionuclides . . . . .479
<b>Part 4 Pharmaceutical Testing, Analysis, and Control</b>	
30	Analysis of Medicinals . . . . .495
31	Biological Testing . . . . .553
32	Clinical Analysis . . . . .565
33	Chromatography . . . . .599
34	Instrumental Methods of Analysis . . . . .633
35	Dissolution . . . . .672
<b>Part 5 Pharmaceutical Manufacturing</b>	
36	Separation . . . . .691
37	Powders . . . . .702
38	Property-Based Drug Design and Preformulation . . . . .720
39	Solutions, Emulsions, Suspensions, and Extracts . . . . .745
40	Sterilization . . . . .776
41	Parenteral Preparations . . . . .802
42	Intravenous Admixtures . . . . .837
43	Ophthalmic Preparations . . . . .850
44	Medicated Topicals . . . . .871
45	Oral Solid Dosage Forms . . . . .889
46	Coating of Pharmaceutical Dosage Forms . . . . .929
47	Extended-Release and Targeted Drug Delivery Systems . . . . .939
48	The New Drug Approval Process and Clinical Trial Design . . . . .965
49	Biotechnology and Drugs . . . . .976
50	Aerosols . . . . .1000
51	Quality Assurance and Control . . . . .1018
52	Stability of Pharmaceutical Products . . . . .1025
53	Bioavailability and Bioequivalency Testing . . . . .1037
54	Plastic Packaging Materials . . . . .1047
55	Pharmaceutical Necessities . . . . .1058
<b>Part 6 Pharmacokinetics and Pharmacodynamics</b>	
56	Diseases: Manifestations and Pathophysiology . . . . .1095
57	Drug Absorption, Action, and Disposition . . . . .1142
58	Basic Pharmacokinetics and Pharmacodynamics . . . . .1171
59	Clinical Pharmacokinetics and Pharmacodynamics . . . . .1191
60	Principles of Immunology . . . . .1206
61	Adverse Drug Reactions and Clinical Toxicology . . . . .1221
62	Pharmacogenomics . . . . .1230
63	Pharmacokinetics/Pharmacodynamics in Drug Development . . . . .1249
<b>Part 7 Pharmaceutical and Medicinal Agents</b>	
64	Diagnostic Drugs and Reagents . . . . .1261
65	Topical Drugs . . . . .1277
66	Gastrointestinal and Liver Drugs . . . . .1294
67	Blood, Fluids, Electrolytes, and Hematological Drugs . . . . .1318
68	Cardiovascular Drugs . . . . .1350
69	Respiratory Drugs . . . . .1371
70	Sympathomimetic Drugs . . . . .1379
71	Cholinomimetic Drugs . . . . .1389
72	Adrenergic Antagonists and Adrenergic Neuron Blocking Drugs . . . . .1399
73	Antimuscarinic and Antispasmodic Drugs . . . . .1405
74	Skeletal Muscle Relaxants . . . . .1411
75	Diuretic Drugs . . . . .1422
76	Uterine and Antimigraine Drugs . . . . .1432
77	Hormones and Hormone Antagonists . . . . .1437
78	General Anesthetics . . . . .1474
79	Local Anesthetics . . . . .1479
80	Antianxiety Agents and Hypnotic Drugs . . . . .1486
81	Antiepileptic Drugs . . . . .1501
82	Psychopharmacologic Agents . . . . .1509
83	Analgesic, Antipyretic, and Anti-Inflammatory Drugs . . . . .1524
84	Histamine and Antihistaminic Drugs . . . . .1543
85	Central Nervous System Stimulants . . . . .1551
86	Antineoplastic Drugs . . . . .1556
87	Immunoactive Drugs . . . . .1588
88	Parasiticides . . . . .1595
89	Immunizing Agents and Allergenic Extracts . . . . .1600
90	Anti-Infectives . . . . .1626
91	Enzymes . . . . .1685
92	Nutrients and Associated Substances . . . . .1688
93	Pesticides . . . . .1719
<b>Part 8 Pharmacy Practice</b>	
<b>A Fundamentals of Pharmacy Practice</b>	
94	Application of Ethical Principles to Practice Dilemmas . . . . .1745
95	Technology and Automation . . . . .1753
96	The Patient: Behavioral Determinants . . . . .1762
97	Patient Communication . . . . .1770
98	Patient Compliance . . . . .1782
99	Drug Education . . . . .1796

100	Professional Communications	1808	117	Documenting, Billing, and Reimbursement for Pharmaceutical Care Services	2114
101	The Prescription	1823	118	Pharmaceutical Risk Management	2124
102	Providing a Framework for Ensuring Medication Use Safety	1840	119	Integrated Health Care Delivery Systems	2130
103	Poison Control	1881		<b>C Patient Care</b>	
104	Drug Interactions	1889	120	Specialization in Pharmacy Practice	2155
105	Extemporaneous Prescription Compounding	1903	121	Pharmacists and Disease State Management	2163
106	Nuclear Pharmacy Practice	1913	122	Development of a Pharmacy Care Plan and Patient Problem-Solving	2170
107	Nutrition in Pharmacy Practice	1925	123	Ambulatory Patient Care	2179
108	Pharmacoepidemiology	1958	124	Self-Care	2197
109	Surgical Supplies	1968	125	Diagnostic Self-Care	2206
110	Health Accessories	1979	126	Preventive Care	2223
	<b>B Social, Behavioral, Economic, and Administrative Sciences</b>		127	Hospital Pharmacy Practice	2247
111	Laws Governing Pharmacy	2015	128	Emergency Medicine Pharmacy Practice	2265
112	Re-engineering Pharmacy Practice	2055	129	Long-Term Care	2272
113	Pharmacoeconomics	2070	130	Aseptic Processing for Home Infusion Pharmaceuticals	2290
114	Community Pharmacy Economics and Management	2082	131	The Pharmacist's Role in Substance Use Disorders	2303
115	Product Recalls and Withdrawals	2098	132	Complementary and Alternative Medical Health Care	2318
116	Marketing Pharmaceutical Care Services	2107	133	Chronic Wound Care	2342

# Plastic Packaging Materials

Barrett E Rabinow, PhD  
Theodore J Roseman, PhD



As defined by the American Society for Testing and Materials (ASTM), a plastic is a material that contains as an essential ingredient one or more polymeric organic substances of large molecular weight, is solid in its finished state and at some stage in its manufacture or processing into finished articles can be shaped by flow. The large-molecular-weight organic substance is called a polymer.

The use of plastics in the health care industry has grown at a very rapid rate since the 1960s. This phenomenal growth is due primarily to the wide flexibility in choice of properties offered by plastics. However, because of the wide range of properties of plastics, judicious selection must be made for the intended application.

Prior to the recognition of the potential use of plastics in health care practice, glass was the predominate material used in the primary packaging of pharmaceutical products. Glass has a definite advantage in being a relatively unreactive and an inert substance (although leachable aluminum and glass particles or delamination have occasionally posed problems). As such, it can be used in contact with many critical products, either dry or liquid. It provides excellent protection against water vapor and gas permeation, and it can withstand steam sterilization (autoclaving) without incurring physical distortion. Two definite disadvantages of glass in the field of packaging, however, are its fragility and weight. Because of these negative aspects, coupled with the many positive attributes of plastics, significant inroads for the use of plastic in pharmaceutical packaging have been made. Today, for example, plastics are being used in the following primary packaging areas, where in the 1960s only glass could be considered: syringes, bottles, vials, and ampules.

There are many other significant medical uses that, without the use of plastics, would never have been technically feasible. A few examples include indwelling catheters, prosthetic devices, tracheotomy tubes, unit dose packaging, and flexible containers for intravenous, irrigation, and inhalation solutions, as well as for the collection of blood. An additional use for plastics is in secondary container packaging (ie, packaging that is not in direct contact with the product itself). This particular use normally involves plastic films of various types and thicknesses used for tamper-proof overwrapping, whereas the previously mentioned devices normally are fabricated by molding or extrusion of the finished part.

Selection of the appropriate materials for a packaging application should be performed with an understanding of the intended overall design of the package. The requirements should be specified with regard to customer usage, regulatory approval, marketing presentation, toxicological considerations,

manufacturability, sterility, and, very importantly, protection of the pharmaceutical product or device during transportation, storage, and use. These functional requirements then must be analyzed in terms of the stress requirements they impose on the material, permitting translation of those requirements into material properties. A target material profile is developed by assigning required values of design and performance properties that predict or correlate with the container functions. Likely candidate materials are determined by comparing their properties with the property profile derived from the functional requirements. A prototype is built and tested via functionally oriented tests such as maintenance of product stability, simulated usage and storage tests, and customer focus groups. These concepts are embodied in ISO 11607.<sup>1</sup> Material properties affecting functional performance are described below.

## MATERIAL PROPERTIES

### Mechanical Properties

Important mechanical properties in plastic packaging materials are:

*Tensile strength*—the maximum force needed to pull apart a specimen of material, divided by its cross-sectional area. Elongation is the percentage change over original length at breaking point and measures a film's ability to stretch.

*Impact strength*—a measure of the ability to withstand shock-loading, in which a specimen receives a blow from a swinging pendulum, for example. Fracture will occur if the impact force exceeds the limit of elasticity of the material. Glass, for example, has a much lower impact strength than many plastics, although it has appreciable tensile strength.

*Tear strength*—measured both as the force necessary to initiate a tear and force to propagate a tear. Propagation of tear is undesirable in shipping sacks but desirable in tear tapes. Orientation of the material can affect results, because the polymer chains can be aligned along a particular direction during manufacturing, thus conferring greater strength in that direction.

*Stiffness*—the resistance of bending where deflection against a load can be measured.

*Flex resistance* to the development of pinholing and fracture, when subjected to repeated flexing or creasing, is important in shipping applications. Unsupported aluminum foil, unless it is heavy gauge, is prone to this failure mode.

*Coefficient of friction or slip*—relates to the ease with which one material will slide over another. Passage of films through

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.